^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Zejula (niraparib) (PARP inhibitor) + Jemperli (dostarlimab-gxly) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): Cohort A of the OPAL trial
Published date:
03/19/2021
Excerpt:
Triplet therapy with niraparib, dostarlimab, and bev is tolerable and demonstrated clinical activity in pts with PROC, most of which were BRCA mutation…
Trial ID:
